Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population-based analysis

International Journal of Cancer

Volumn 121, Issue 5, 2007, Pages 1079-1085

  Sherman, Mark E ^a   Rimm, David L ^b   Yang, Xiaohong R ^a   Chatterjee, Nilanjan ^a   Brinton, Louise A ^a   Lissowska, Jolanta ^c   Peplonska, Beata ^d   Szeszenia Da̧browska, Neonila ^d   Zatonski, Witold ^c   Cartun, Richard ^e   Mandich, Daniza ^e   Rymkiewicz, Grzegorz ^c   Ligaj, Marcin ^c   Lukaszek, Stanisław ^f   Kordek, Radzislaw ^g   Kalaylioglu, Zynep ^h   Harigopal, Malini ^b   Charrette, Lori ^b   Falk, Roni T ^a   Richesson, Douglas ^a   Anderson, William F ^a   Hewitt, Stephen M ^a   García Closas, Montserrat ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^e HARTFORD HOSPITAL   (United States)

^f POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^g MEDICAL UNIVERSITY OF LODZ   (Poland)

^h IMS   (United States)

Author keywords

Breast; Epidemiology; Etiology; Hormones

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HORMONE RECEPTOR;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CASE REPORT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; GENETIC VARIABILITY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; POLAND; POPULATION RESEARCH; PREMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; TISSUE MICROARRAY;

ADULT; AGED; BODY MASS INDEX; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POPULATION SURVEILLANCE; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547095767     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22812     Document Type: Article

References (29)

1. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer 2004;11497-522.
2. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
4. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-1568.
5. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 2006;8:R43.
6. Garcia-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Blair A, Kalaylioglu Z, Rymkiewicz G, et al. Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer 2006;95:123-9.
7. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-15.
8. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323-7.
9. Chatterjee N. A two-stage regression model for epidemiological studies with multivariate disease classification data. J Am Stat Assoc 2004;99:127-38.
10. Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001;10:139-52.
11. Fergenbaum JH, Garcia-Closas M, Hewitt SM, Lissowska J, Sakoda LC, Sherman ME. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev 2004;13:667-72.
12. DiVito KA, Charette LA, Rimm DL, Camp RL. Long-term preservation of antigenicity on tissue microarrays. Lab Invest 2004;84:1071-8.
13. Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6.
14. Saunders PT, Millar MR, Williams K, Macpherson S, Bayne C, O'Sullivan C, Anderson TJ, Groome NP, Miller WR. Expression of oestrogen receptor β (ERβ1) protein in human breast cancer biopsies. Br J Cancer 2002;86:250-6.
15. Miyoshi Y, Akazawa K, Kamigaki S, Ueda S, Yanagisawa T, Inoue T, Yamamura J, Taguchi T, Tamaki Y, Noguchi S. Prognostic significance of intra-tumoral estradiol level in breast cancer patients. Cancer Lett 2004;216:115-21.
16. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996;88:756-8.
17. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
18. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201.
19. Fentiman IS, Hanby A, Allen DS, Key T, Meilahn EN. Hormone dependency of breast tumours developing in the Guernsey Cohort Study. Breast Cancer Res Treat 2006;97:205-8.
20. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856-65.
21. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ, Hudis C, Brown AM, et al. HER-2/neu-induced mammary tumorigenesis and angiogenesis are reduced incyclooxygenase-2 knockout mice. Cancer Res 2005;65:10113-9.
22. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-61.
23. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, Borg A, Ferno M, Peterson C, Meltzer PS. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
24. Khan SA, Sachdeva A, Naim S, Meguid MM, Marx W, Simon H, Halverson JD, Numann PJ. The normal breast epithelium of women with breast cancer displays an aberrant response to estradiol. Cancer Epidemiol Biomarkers Prev 1999;8:867-72.
25. Shoker BS, Jarvis C, Clarke RB, Anderson E, Hewlett J, Davies MP, Sibson DR, Sloane JP. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999;155:1811-15.
26. Ness RB, Buhari A, Gutai J, Kuller LH. Reproductive history in relation to plasma hormone levels in healthy post-menopausal women. Maturitas 2000;35:149-57.
27. Matthews J, Wihlen B, Tujague M, Wan J, Strom A, Gustafsson JA. Estrogen receptor (ER) β modulates ERα-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 2006;20:534-43.
28. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 2005;56(Suppl 1):21-6.
29. Allred DC, Brown P, Medina D. The origins of estrogen receptor expositive and estrogen receptor α-negative human breast cancer. Breast Cancer Res 2004;6:240-5.